Factor VIII inhibitor and source of replacement therapy

Lignende værker

• Recommendations for factor VIII product source to treat patients with haemophilia A
  af: Arcieri, Romano, et al.
  Udgivet: (2017)
• Further comments on “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis”
  af: Messori, Andrea, et al.
  Udgivet: (2019)
• Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement
  af: Santagostino, Elena, et al.
  Udgivet: (2019)
• Factor VIII replacement is still the standard of care in haemophilia A
  af: Aledort, Louis, et al.
  Udgivet: (2019)
• The increased demand for plasma-derived factor VIII in Italy
  af: Arcieri, Romano, et al.
  Udgivet: (2017)